245
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Cytogenotoxic effects of venlafaxine hydrochloride on cultured human peripheral blood lymphocytes

& ORCID Icon
Pages 192-199 | Received 12 Feb 2018, Accepted 31 May 2018, Published online: 20 Jul 2018

References

  • Albertini, R.J., et al., 2000. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. International Programme on Chemical Safety. Mutation Research, 463 (2), 111–172.
  • Albrecht, C., Borm, P.J.A., and Unfried, K., 2004. Signal transduction pathways relevant for neoplastic effects of fibrous and non-fibrous particles. Mutation Research, 553 (1–2), 23–35.
  • Attia, S.M. and Bakheet, S.A., 2013. Citalopram at the recommended human doses after long-term treatment is genotoxic for male germ cell. Food and Chemical Toxicology, 53, 281–285.
  • Barlow, D.H., 2000. Venlafaxine for hot flushes. Lancet (London, England), 356 (9247), 2025–2026.
  • Bradley, M.O., et al., 1981. Mutagenesis by chemical agents in V79 Chinese hamster cells: a review and analysis of the literature. A Report of the Gene–Tox Program. Mutation Research, 87 (2), 81–142.
  • Brambilla, G. and Martelli, A., 2009. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutation Research, 681 (2–3), 209–229.
  • Brambilla, G. and Martelli, A., 2007. Genotoxic and carcinogenic risk to humans of drug-nitrite interaction products. Mutation Research, 635 (1), 17–52.
  • Brambilla, G., Mattioli, F., and Martelli, A., 2009. Genotoxic and carcinogenic effects of antipsychotics and antidepressants. Toxicology, 261 (3), 77–88.
  • Brion, J. D., 2003. Agents Alkylants: généralités médicaments anti-tumoraux et perspectives dans le traitement des cancers. Paris: TEC & DOC.
  • Cobanoglu, H., et al., 2018. In vitro genotoxic and cytotoxic effects of doxepin and escitalopram on human peripheral lymphocytes. Drug and Chemical Toxicology, 41 (2), 238–244.
  • Cosgrove, L., et al., 2011. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers’ financial associations with industry. PLoS One, 6 (4), e18210.
  • Cotterchio, M., et al., 2000. Antidepressant medication use and breast cancer risk. American Journal of Epidemiology, 151 (10), 951–957.
  • Das, P.G., Shaik, A.P., and Jamil, K., 2006. Estimation of apoptosis and necrosis caused by pesticides in vitro on human lymphocytes using DNA diffusion assay. Drug and Chemical Toxicology, 29 (2), 147–156.
  • Diamond, S., 1995. Efficacy and safety profile of venlafaxine on chronic headache. Headache Quarterly, 6 (3), 212–214.
  • Donbak, L., Dal, O., and Celik, M., 2014. Genotoxic effects of antidepressant reboxetine in human peripheral lymphocytes. Advance Laboratory Medicine International, 4 (3), 93–102.
  • Draz, E.I., et al., 2009. Genotoxicity of some commonly used antidepressants (fluoxetine, sertraline and clomipramine). Mansoura Journal of Forensic Medicine & Clinical Toxicology, 17 (2), 63–77.
  • Elmorsy, E., et al., 2017. Antidepressants are cytotoxic to rat primary blood brain barrier endothelial cells at high therapeutic concentrations. Toxicology in Vitro, 44, 154–163.
  • Evans, H. J., 1984. Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. In: B.J. Kilbey, M. Legator, W. Nichols and C. Ramel, eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier Science Publishers, 405–427.
  • Food and Drug Administration (FDA), 2008. Center for drug evaluation and research, medical review(s). Application Number: 22-104 [online]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022104s000_MedR.pdf [Accessed 8 October 2017].
  • Fenech, M., 2000. The in vitro micronucleus technique. Mutation Research, 455 (1–2), 81–95.
  • Fenech, M., 2007. Cytokinesis-block micronucleus cytome assay. Nature Protocols, 2 (5), 1084–1104.
  • Fenech, M., et al., 2011. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis, 26 (1), 125–132.
  • Fenech, M. and Bonassi, S., 2011. The effect of age, gender, diet and lifestyle on DNA damage measured using micronucleus frequency in human peripheral blood lymphocytes. Mutagenesis, 26 (1), 43–49.
  • Hassanane, M.S., et al., 2012. Genotoxic evaluation for the tricyclic antidepressant drug, amitriptyline. Drug and Chemical Toxicology, 35 (4), 450–455.
  • Holland, J. F. and Frei, E., 2003. Holland-Frei cancer medicine. 6th ed. Hamilton, ON: BC Decker Inc.
  • International Test Commission (ITC), 2014. ITC guidelines on quality control in scoring, test analysis, and reporting of test scores. International Journal of Testing, 14 (3), 195–217.
  • Jenkins, G.J.S., et al., 2005. Do dose response thresholds exist for genotoxic alkylating agents? Mutagenesis, 20 (6), 389–398.
  • Kirkland, D.J. and Müller, L., 2000. Interpretation of the biological relevance of genotoxicity test results: the importance of thresholds. Mutation Research, 464 (1), 137–147.
  • Kirsch-Volders, M., et al., 2011. The in vitro MN assay in 2011: origin and fate, biological significance, protocols, high throughput methodologies and toxicological relevance. Archives of Toxicology, 85 (8), 873–899.
  • Kirsch-Volders, M., et al., 1997. The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutation Research, 392 (1–2), 19–30.
  • Kirsch-Volders, M., et al., 2003. Report from the in vitro micronucleus assay working group. Mutation Research, 540 (2), 153–163.
  • Kocaman, A.Y. and Bucak, S., 2016. Genotoxic and cytotoxic effects of flumetralin in human peripheral blood lymphocytes in vitro. Toxicology and Industrial Health, 32 (12), 1927–1934.
  • Kocaman, A.Y. and Topaktaş, M., 2007. In vitro evaluation of the genotoxicity of acetamiprid in human peripheral blood lymphocytes. Environmental and Molecular Mutagenesis, 48 (6), 483–490.
  • Lacaze, E., et al., 2015. Genotoxic and immunotoxic potential effects of selected psychotropic drugs and antibiotics on blue mussel (Mytilus edulis) hemocytes. Environmental Pollution, 202, 177–186.
  • Madle, S., Beek, B., and Nowak, C., 1993. Zum Verständnis von Chromosomenmutationstest an Somazellen. In: R. Fahrig, ed. Mutationsforschung und genetische toxikologie. Darmstadt, Germany: Wissenschaftliche Buchgesellschaft, 224–242.
  • Madrigal-Bujaidar, E., et al., 2015. Evaluation of duloxetine as micronuclei inducer in an acute and a subchronic assay in mouse. Biological and Pharmaceutical Bulletin, 38 (8), 1245–1249.
  • Metcalfe, C.D., et al., 2010. Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed. Environmental Toxicology and Chemistry, 29 (1), 79–89.
  • Mosesso, P., et al., 2013. In vitro cytogenetic assays: chromosomal aberrations and micronucleus tests. In: A. Dhawan and M. Bajpayee, eds. Genotoxicity assessment: methods and protocols, methods in molecular biology. New York: Springer Science + Business Media, 1044, 123–146.
  • Müller, L. and Kasper, P., 2000. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutation Research, 464 (1), 19–34.
  • Norppa, H. and Falck, G.C.-M., 2003. What do human micronuclei contain? Mutagenesis, 18 (3), 221–233.
  • Obe, G. and Durante, M., 2010. DNA double strand breaks and chromosomal aberrations. Cytogenetic and Genome Research, 128 (1–3), 8–16.
  • Organisation for Economic Co-operation and Development (OECD), 2014. Guideline for the testing of chemicals. In vitro mammalian cell micronucleus test, 487 [online]. Available from: https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecd-tg487-2014-508.pdf [Accessed 8 October 2017].
  • Paniagua-Pérez, R., et al., 2002. Sister chromatid exchanges produced by imipramine and desipramine in mouse bone marrow cells treated in vivo. Toxicology Letters, 132 (2), 123–129.
  • Paz-y-Miño, C., et al., 2002. Cytogenetic monitoring in a population occupationally exposed to pesticides in Ecuador. Environmental Health Perspectives, 110 (11), 1077–1080.
  • PDR, 2005. Physicians’ desk reference. 59th ed. Montvale, NJ: Thomson PDR.
  • Pereira, P., et al., 2009. Neurobehavioral and genotoxic parameters of duloxetine in mice using the inhibitory avoidance task and comet assay as experimental models. Pharmacological Research, 59 (1), 57–61.
  • Preston, R.J., San Sebastian, J.R., and McFee, A.F., 1987. The in vitro human lymphocyte assay for assessing the clastogenicity of chemical agents. Mutation Research, 189 (2), 175–183.
  • Puyo, S., Montaudon, D., and Pourquier, P., 2014. From old alkylating agents to new minor groove binders. Critical Reviews in Oncology/Hematology, 89 (1), 43–61.
  • Reddy, M.S., 2012. Depression - the global crisis. Indian Journal of Psychological Medicine, 34 (3), 201–203.
  • Rosetti, M., et al., 2006. Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. Journal of Experimental Therapeutics & Oncology, 6 (1), 23–29.
  • Rothfuss, A., et al., 2000. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Research, 60 (2), 390–394.
  • Sansone, R.A. and Sansone, L.A., 2014. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innovations in Clinical Neuroscience, 11 (3–4), 37–42.
  • Sayar, K., et al., 2003. Venlafaxine treatment of fibromyalgia. The Annals of Pharmacotherapy, 37 (11), 1561–1565.
  • Schaik, N.V. and Graf, U., 1991. Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test of Drosophila melanogaster. Mutation Research, 260 (1), 99–104.
  • Silva, A.M., et al., 2016. Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity. Food and Chemical Toxicology, 94, 148–158.
  • Snyder, R.D., Ewing, D., and Hendry, L.B., 2006. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutation Research, 609 (1), 47–59.
  • Snyder, R.D., 2009. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environmental and Molecular Mutagenesis, 50 (6), 435–450.
  • Snyder, R.D., et al., 2005. The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mutation Research, 578 (1–2), 88–99.
  • Snyder, R.D. and Brown, J.E., 2002. Evidence for and role of the dimethylamino group in Tamoxifen DNA intercalation in intact Chinese hamster V79 cells. Drug and Chemical Toxicology, 25 (4), 473–479.
  • Steingart, A., et al., 2003. Antidepressant medication use and breast cancer risk: a case-control study. International Journal of Epidemiology, 32 (6), 961–966.
  • Sumpton, J.E. and Moulin, D.E., 2001. Treatment of neuropathic pain with venlafaxine. The Annals of Pharmacotherapy, 35 (5), 557–559.
  • Tazehkand, M.N. and Topaktas, M., 2015. The in vitro genotoxic and cytotoxic effects of remeron on human peripheral blood lymphocytes. Drug and Chemical Toxicology, 38 (3), 266–271.
  • Vock, E.H., et al., 1998. Discrimination between genotoxicity and cytotoxicity in the induction of DNA double-strand breaks in cells treated with etoposide, melphalan, cisplatin, potassium cyanide, Triton X-100 and c-irradiation. Mutation Research, 413 (1), 83–94.
  • Weintein, I.B., 1988. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment twenty–seventh G.H.A. Cloves memorial award lecture. Cancer Research, 48, 4135–4143.
  • World Health Organisation (WHO), 2012. Depression: a global public health concern [online]. Available from: http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf [Accessed 8 October 2017].
  • Yilmaz, E.A., Unal, F., and Yuzbasioglu, D., 2017. Evaluation of cytogenetic and DNA damage induced by the antidepressant drug-active ingredients, trazodone and milnacipran, in vitro. Drug and Chemical Toxicology, 40 (1), 57–66.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.